Shares of Coherus BioSciences Inc. (NASDAQ:CHRS) were down 6.6% on Thursday . The company traded as low as $23.82 and last traded at $24.37, with a volume of 208,003 shares. The stock had previously closed at $26.10.

Separately, Zacks Investment Research cut shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Tuesday, May 3rd.

The stock has a 50 day moving average price of $18.18 and a 200-day moving average price of $17.91. The company’s market capitalization is $938.60 million.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings data on Monday, May 9th. The company reported ($1.67) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.42) by $0.25. On average, equities research analysts anticipate that Coherus BioSciences Inc. will post ($5.90) EPS for the current fiscal year.

In related news, insider Peter K. Watler sold 43,495 shares of Coherus BioSciences stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $20.02, for a total value of $870,769.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alan C. Herman sold 4,250 shares of Coherus BioSciences stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $19.20, for a total value of $81,600.00. Following the completion of the sale, the insider now owns 207,167 shares of the company’s stock, valued at $3,977,606.40. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Coherus BioSciences stock. Jennison Associates LLC boosted its position in Coherus BioSciences Inc. (NASDAQ:CHRS) by 3.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 367,021 shares of the company’s stock after buying an additional 11,023 shares during the period. Jennison Associates LLC owned 0.94% of Coherus BioSciences worth $8,427,000 at the end of the most recent reporting period.

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.